Actinium Pharmaceuticals (ATNM) Other financing activities (2013 - 2024)
Actinium Pharmaceuticals (ATNM) posted quarterly Other financing activities of $75000.0 for Q1 2024, up 7400.0% year-over-year from $1000.0 in Q2 2023, and down 71.26% quarter-over-quarter from $261000.0 in Q2 2023.
Actinium Pharmaceuticals (ATNM) Other financing activities (2013 - 2024) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Other financing activities for 8 consecutive years, with $75000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Other financing activities rose 7400.0% year-over-year to $75000.0; the TTM figure through Dec 2024 stood at $75000.0 (down 71.37% YoY), while the FY2024 annual figure was $75000.0, down 71.37% from the prior year.
- Other financing activities retreated to $75000.0 in Q1 2024 per ATNM's latest filing, from $261000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $261000.0 in Q2 2023 and bottomed at -$3000.0 in Q3 2020.
- Historically, Other financing activities has averaged $76000.0 across 3 years, with a median of $46000.0 in 2020.
- On a YoY basis, Other financing activities climbed as much as 7400.0% in 2024 and fell as far as 7400.0% in 2024.
- Actinium Pharmaceuticals' Other financing activities stood at $46000.0 in 2020, then surged by 467.39% to $261000.0 in 2023, then slumped by 71.26% to $75000.0 in 2024.
- Business Quant data shows ATNM's Other financing activities at $75000.0 in Q1 2024, $261000.0 in Q2 2023, and $1000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 75,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Jun 30, 2023 | 261,000.00 |
| Jun 30, 2023 | 261,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2020 | 46,000.00 |
| Dec 31, 2020 | 46,000.00 |
| Sep 30, 2020 | -3,000.00 |
| Sep 30, 2020 | -3,000.00 |
| Jun 30, 2019 | 238.00 |
| Jun 30, 2019 | 238.00 |
| Mar 31, 2019 | 1.50 Mn |
| Mar 31, 2019 | 1.50 Mn |
| Sep 30, 2018 | 3,949.00 |
| Sep 30, 2018 | 3,949.00 |
| Jun 30, 2018 | -13.80 Mn |
| Jun 30, 2018 | -13.80 Mn |
| Mar 31, 2018 | 13.80 Mn |
| Mar 31, 2018 | 13.80 Mn |